This bill creates the Office of Climate Change and Health Equity within the Department of Health and Human Services to coordinate federal efforts addressing climate change's health impacts, with special focus on environmental justice communities and medically underserved populations. It requires the development of a National Strategic Action Plan within one year of enactment, to be updated annually, that identifies climate-related health risks and outlines strategies to protect vulnerable communities. The bill also establishes a science advisory board of experts and authorizes $10 million annually for the Office through fiscal year 2031 to support activities including tracking climate health risks, developing preparedness plans, and reducing greenhouse gas emissions in the health sector.
This bill prohibits federal health plans (like the Federal Employees Health Benefits program) from covering gender-affirming care for individuals under 18 years old. It defines gender-affirming care broadly as medical interventions for gender dysphoria, including hormone therapy, puberty blockers, and surgeries, but includes specific exceptions for medically necessary treatments like precocious puberty, disorders of sexual development, and injuries requiring immediate care. The bill allows ongoing hormone therapy for minors already receiving it as of the effective date to continue for up to one year under a physician-supervised reduction plan. It applies only to federal health plans, not private insurance or other programs.
This bill prioritizes states that have never received a Department of Veterans Affairs (VA) suicide prevention grant. It requires the VA Secretary to give all eligible applicants in such states a scoring preference during grant evaluations until at least one grant is awarded there. The law directly affects veterans in states without existing VA suicide prevention grants by ensuring these states receive fair consideration for funding. Key mechanisms include prioritizing entities in states with prior unawarded applications and applying a scoring preference for all applicants in states with no prior grants. This aims to expand access to mental health support for veterans nationwide.
This bill requires Medicaid, Children's Health Insurance Program (CHIP), and private health plans to cover human milk fortifier - specialized nutritional products made from donor human milk - without cost-sharing for eligible premature infants. It directly affects infants under 1 year with specific medical needs, such as birth at 34 weeks or less, birth weight under 1,800 grams, or certain health conditions requiring this fortifier. Key provisions mandate no deductibles or copays for this coverage starting January 1, 2026, and define eligibility criteria for healthcare providers to determine medical necessity. The law applies broadly across federal health programs and private insurance, ensuring access to this nutrition support for qualifying infants.
HR 1414, titled "Cameron’s Law," increases the tax credit for pharmaceutical companies developing orphan drugs (medicines for rare diseases) from 25% to 50% of qualified research expenses. This change directly affects drug manufacturers investing in treatments for conditions affecting fewer than 200,000 people in the U.S. The bill amends the Internal Revenue Code to implement this higher credit rate, effective for taxable years starting after the law’s enactment. It provides a concrete financial incentive to encourage research into rare disease treatments without altering eligibility criteria or adding new requirements.
The SAVES Act of 2025 establishes a five-year pilot program at the Department of Veterans Affairs (VA) to fund nonprofit organizations that provide service dogs to eligible veterans with specific disabilities, such as blindness, mobility issues, PTSD, or traumatic brain injury. Nonprofits must apply competitively, meet training and animal welfare standards (including ADA compliance), and provide service dogs at no cost to veterans, with the VA covering all program expenses. The VA will also provide ongoing veterinary insurance for the dogs, which continues even after the pilot ends. This program is funded with $10 million annually for five years, targeting veterans as defined by VA medical criteria.
The Stop STALLING Act empowers the Federal Trade Commission (FTC) to take action against pharmaceutical companies that submit "sham" petitions under drug approval processes. Specifically, it targets petitions that are objectively baseless and used to delay generic drug approvals, directly affecting drug manufacturers filing such petitions. The bill establishes civil penalties of up to $50,000 per day or the revenue earned from the delayed drug during the petition's review period. It creates a presumption of "sham" status if the Health Secretary determines a petition was filed primarily to delay approval, with companies able to rebut this presumption. The law does not alter FDA drug approval rules but adds FTC enforcement for unfair competition tactics.
HRES 276 is a non-binding resolution recognizing racial disparities in colorectal cancer outcomes for the Hispanic community. It specifically highlights that Hispanic adults are less likely to receive screening (49% vs. 58% for non-Hispanic White adults) despite colorectal cancer being a leading cause of cancer death in this group. The resolution encourages the CDC to research screening disparities and develop strategies to reduce them, while also supporting National Colorectal Cancer Awareness Month in March. It urges individuals to discuss screening with healthcare providers and calls for NIH research on risk factors in young adults. This resolution does not create new laws or funding but aims to raise awareness and guide future public health efforts.
HR 5364, the STOP FRAUD in Medicaid Act, expands state Medicaid fraud control units' authority to investigate and prosecute fraud committed by Medicaid beneficiaries (people receiving benefits), not just healthcare providers. It amends federal law to explicitly include "individuals applying for or receiving" Medicaid services in fraud investigations, requiring states to cover both provider and beneficiary fraud. The bill directs states to investigate false applications or misuse of benefits, such as lying about income to qualify or using benefits for unauthorized services. These changes take effect 180 days after the bill becomes law, applying to all Medicaid programs nationwide. The law focuses on clarifying investigative scope without creating new penalties or funding.
S 2951, the Competitive Bidding Relief Act, extends current Medicare payment rates for durable medical equipment (DME) in non-rural areas through December 31, 2025, and delays a new payment rule until 2026. It directly affects Medicare beneficiaries and DME suppliers in non-rural communities by maintaining existing reimbursement rates. The bill modifies how the Medicare program calculates payments under Section 414.210(g)(9) of federal regulations, preventing immediate changes to payment structures. This provides temporary stability for DME providers while allowing the government time to implement future adjustments.
